Welcome to our dedicated page for CAMP4 Therapeutics news (Ticker: CAMP), a resource for investors and traders seeking the latest updates and insights on CAMP4 Therapeutics stock.
CAMP4 Therapeutics Corporation reports developments as a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics designed to upregulate gene expression and restore healthy protein levels in genetic diseases. Company updates center on its RAP Platform, regRNA mapping, antisense oligonucleotide candidates and CMP-002 for SYNGAP1-related disorder, along with regulatory submissions, orphan-drug designation and natural-history research collaborations.
Recurring news also includes financial results, research and development spending, financing activity, business-development agreements such as the GSK collaboration, board and governance changes, inducement equity grants under Nasdaq rules and investor conference participation.
CAMP4 Therapeutics (CAMP) has received authorization from the UK Medicines and Healthcare products Regulatory Agency to include United Kingdom sites in its planned global Phase 1/2 clinical trial of CMP-002 for patients with SYNGAP1-related disorder.
The MHRA decision builds on clearances obtained in July 2026 from Australia’s Therapeutic Goods Administration and local Human Research Ethics Committee, and from Argentina’s ANMAT, all supporting initiation of first-in-human studies of CMP-002. The company anticipates starting the Phase 1/2 trial in the fourth quarter of 2026 and has additional regulatory filings under review in the European Union.
CAMP4 Therapeutics (CAMP) will host a virtual Analyst Day on September 28, 2026, from 12:00–1:30 PM ET to discuss CMP-002 for SYNGAP1-related disorder.
The event will feature CAMP4 leadership, a leading KOL, and patient advocates, covering unmet clinical need, the Phase 1/2 first-in-human trial design for CMP-002 expected to initiate in Q4 2026, and an update on the early discovery pipeline. The live webcast and 30-day replay will be available via the company’s investor relations website.
CAMP4 Therapeutics (Nasdaq: CAMP) will participate in two upcoming investor conferences. The company plans 1x1 meetings at the Wells Fargo 21st Annual Healthcare Conference in Boston on September 8, 2026, and a fireside chat plus 1x1 meetings at the Cantor Global Healthcare Conference in New York on September 9, 2026 at 1:00 p.m. ET. Live webcasts and a 30-day replay of the Cantor presentation will be available on CAMP4’s investor relations website.
CAMP4 Therapeutics (Nasdaq: CAMP) reported second quarter 2026 results and regulatory progress for its lead program CMP-002 for SYNGAP1-related disorder. The company obtained regulatory clearance in Australia and Argentina to initiate a first-in-human Phase 1/2 trial, with trial launch expected in Q4 2026, and submitted additional filings in the EU and UK.
CAMP4 closed a fully subscribed second tranche of its private placement, raising $50.1 million in gross proceeds on top of approximately $50 million raised in September 2025, extending its cash runway through year-end 2028. As of June 30, 2026, cash and cash equivalents were $86.4 million, down from $109.5 million at December 31, 2025.
Q2 2026 research and collaboration revenue was $1.78 million versus $1.50 million a year earlier. Research and development expenses were $10.8 million and general and administrative expenses were $4.3 million. Net loss widened to $33.5 million from $12.6 million, primarily due to a $20.9 million non-cash loss from a change in fair value of the derivative tranche liability related to the September 2025 private placement. Total liabilities of $94.1 million exceeded total assets of $93.4 million, resulting in stockholders’ deficit of $0.7 million. CAMP4 also relocated its headquarters to Watertown, Massachusetts and scheduled a Virtual Analyst Day for September 28, 2026.
CAMP4 Therapeutics (Nasdaq: CAMP) closed the second tranche of its previously announced $100 million private placement, raising approximately $50.1 million in gross proceeds. The financing comprised 10,756,498 common shares at $1.53, 39,306 common shares to insiders at $1.65, and 21,925,368 pre-funded warrants at $1.5299 each.
According to CAMP4 Therapeutics, net proceeds will support advancement of CMP-002, including a planned Phase 1/2 trial in SYNGAP1-related disorder in Australia, and ongoing development of its early-stage pipeline. The round included several institutional investors and was led by Leerink Partners as placement agent.
CAMP4 Therapeutics (Nasdaq: CAMP) received clearance from Australia’s Therapeutic Goods Administration and a local Human Research Ethics Committee to initiate a Phase 1/2 first-in-human clinical trial of CMP-002, a potential first-in-class disease-modifying therapeutic for SYNGAP1-related disorder, which currently has no approved treatments.
The TGA clearance also triggers a regulatory milestone under CAMP4’s September 9, 2025 Securities Purchase Agreement. According to the company, CAMP4 previously received approximately $50 million in gross proceeds and is now eligible to raise up to an additional $50 million in gross proceeds through a second closing, issuing up to 32,721,172 shares of common stock or pre-funded warrants. The second closing is expected within five business days, subject to customary conditions, with participation from investors including Coastlands Capital, Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management, Trails Edge Capital Partners, and CURE SYNGAP1.
CAMP4 Therapeutics (Nasdaq: CAMP) reported that on July 15, 2026, its Board Compensation Committee granted a non-qualified stock option to purchase 8,000 shares of common stock to a new employee as an inducement grant under Nasdaq Listing Rule 5635(c)(4).
The option has a 10-year term and an exercise price of $4.21 per share, equal to the closing price on the grant date. Vesting occurs over four years: 25% after one year of employment, then the remaining shares vest in 36 equal monthly installments, subject to continued service. The grant is made under the company’s 2026 Inducement Plan and related stock option agreement.
CAMP4 Therapeutics (Nasdaq:CAMP) granted non-qualified stock options to three new employees under Nasdaq Listing Rule 5635(c)(4). The inducement awards cover an aggregate 39,000 shares at an exercise price of $3.96 per share, equal to the June 15, 2026 closing price.
The options have a 10-year term and vest over four years: 25% after one year of employment, then the remainder in 36 equal monthly installments, subject to continued service. The grants are issued under CAMP4’s 2026 Inducement Plan and related stock option agreements.
CAMP4 Therapeutics (Nasdaq:CAMP) granted a non-qualified stock option to purchase 5,000 shares of common stock to a new employee as an inducement award under Nasdaq Listing Rule 5635(c)(4).
The option has a 10-year term, an exercise price of $4.31, and vests over four years.
CAMP4 Therapeutics (Nasdaq:CAMP) reported new preclinical data for CMP-002, its lead antisense oligonucleotide for SYNGAP1-related disorder (SRD). In a SYNGAP1 haploinsufficient mouse model using pentylenetetrazol-induced seizures, CMP-002 administration produced statistically significant improvements in seizure threshold and tonic-clonic seizure severity. CAMP4 plans to advance CMP-002 into a Phase 1/2 trial in SRD in the second half of 2026.